Steven Pieper - 31 Jan 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
01 Feb 2023, 15:13:10 UTC
Previous filing
09 Aug 2024
Next filing
21 Nov 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +750,000 +188% $0.000000 1,148,912 31 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 These shares include 7,544 shares that were purchased on June 30, 2022 and 2,534 shares that were purchased on December 31, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.

Remarks:

Chief Financial Officer